Klabax (Clarithromycin)

Clarithromycin is a macrolide antibiotic that targets susceptible bacterial pathogens in several infection categories.

• Community‑acquired pneumonia: effective in treating bacterial pneumonia caused by susceptible organisms.
• Acute bacterial sinusitis: reduces symptoms and bacterial load in sinus inflammation.
• Acute otitis media: clears middle‑ear infections caused by typical pathogens.
• Skin and soft‑tissue infections: resolves cellulitis, impetigo and related bacterial skin conditions.
• Helicobacter pylori eradication (in combination therapy): contributes to bacterial clearance when used with other agents.

• Clarithromycin inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking translocation of the peptidyl‑tRNA. This action halts peptide chain elongation, leading to bacteriostatic effects against susceptible gram‑positive, gram‑negative and atypical organisms.

Clarithromycin may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: frequent loose stools.
• Abdominal pain: cramping or discomfort.
• Taste disturbance: altered or metallic taste.
• Headache: mild to moderate pain.
• Vomiting: occasional episodes.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• QT interval prolongation: may lead to cardiac arrhythmias.
• Clostridioides difficile‑associated diarrhea: severe colitis.
• Hepatic enzyme elevation: potential liver injury.
• Stevens‑Johnson syndrome/toxic epidermal necrolysis: life‑threatening skin reactions.
• Severe neutropenia: marked reduction in white blood cells.

Before prescribing clarithromycin, clinicians should consider several safety factors.

• Pregnancy: Category B; use only when the potential benefit justifies the potential risk to the fetus.
• Breastfeeding: excreted in milk; weigh infant benefits against possible adverse effects.
• Hepatic impairment: dose adjustment may be required; monitor liver function tests.
• Cardiac risk: avoid in patients with known QT prolongation or electrolyte disturbances.
• Drug‑resistant organisms: verify susceptibility before use.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Clarithromycin interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Erythromycin and other macrolides: additive risk of QT prolongation.
• Cisapride: may cause serious cardiac arrhythmias.
• Theophylline: clarithromycin can increase serum theophylline concentrations.
• Antacids containing aluminum or magnesium: reduce clarithromycin absorption.

Moderate Interactions (Monitor Closely)

• Warfarin: potential enhancement of anticoagulant effect; monitor INR.
• Statins (e.g., simvastatin): increased risk of myopathy.
• Carbamazepine: may lower clarithromycin plasma levels, reducing efficacy.